Alfredo Silva is a partner in the Corporate Group, is co-chair of the firm's Social Enterprise and Impact Investing Group, and a member of the Pro Bono Committee. Mr. Silva represents public and private companies and investors in a broad range of corporate and securities law matters. Mr. Silva’s practice includes initial public offerings, primary and secondary offerings, private placements, preferred stock financings, public and private mergers and acquisitions, and STOs.
In his public company practice, Mr. Silva also counsels issuers on corporate governance issues, compliance with the U.S. federal securities laws, and compliance with the listing standards of Nasdaq and the New York Stock Exchange.
In his private company practice, Mr. Silva has served as company or investor counsel in venture and late-stage financings, minority strategic investments and impact investments in dozens of private companies, including representation of Intel Corporation in its $740 million acquisition of an 18% stake in Cloudera, Inc., Temasek in its $800 million minority investment in Verily Life Sciences, an Alphabet company, and Visa in its investments in various fintech startups, such as Chain.
Mr. Silva also advises on structuring offerings of cryptocurrencies and other digital tokens in compliance with securities laws, including pre-sales, secondary transactions and token-based compensation programs, as well as guiding public issuers in the blockchain space through filings with the Securities and Exchange Commission.
In addition, Mr. Silva represents nonprofit organizations, providing advice on fiduciary issues, entity formation, structuring and other corporate matters, and assists small businesses pro bono. He incorporated and continues to work with Illuminate, the nonprofit producer of The Bay Lights, a 25,000 LED sculpture on the western span of the San Francisco-Oakland Bay Bridge, in structuring, corporate governance, and project management matters. He is also proud to serve on the board of directors of the San Francisco AIDS Foundation, which he has previously advised on corporate governance matters.
Mr. Silva is recognized by The Recorder as a 2013 Lawyer on the Fast Track, in 2014 was the inaugural recipient of the firm’s Kathi Pugh Award for Pro Bono Service, and is a 2017 Lawyers Committee for Legal Diversity Fellow. He is also recognized as a leading lawyer by Legal 500 in 2019.
Mr. Silva received his B.S. degree, cum laude with distinction, in Engineering Sciences (Chemical) from Yale College in 2004. He received his J.D. degree from Yale Law School in 2008. Mr. Silva speaks conversational Mandarin Chinese, and spent a year at China’s Tsinghua University researching issues in intellectual property protection on a Fulbright Fellowship.
LATE STAGE AND CORPORATE VENTURE CAPITAL FINANCINGS
Temasek's Investment in Verily Life SciencesRepresented Singapore investment fund Temasek in its $800 million investment in Verily Life Sciences, Alphabet/Google's life sciences division.
Intel's Investment in ClouderaRepresented Intel Corporation in its $740 million acquisition of an 18% stake in Cloudera, Inc.
SoftBank Group and SoftBank Vision Fund's Investments in Kabbage, Nauto, and BrainRepresented SoftBank Group, in its $250 million investment in online lending platform Kabbage, Inc., represented co-lead investors, including SoftBank Group, in the $159 million Series B financing of autonomous vehicle company Nauto, and represented SoftBank Vision Fund in the $114 million Series C financing round of AI company Brain Corporation.
Visa's Strategic Investments in the Fintech SpaceRepresented Visa in over a dozen strategic investments in the fintech space, including investments in Chain, Conductor Technologies, Paystack and YellowPepper.
Temasek's Investment in Coherus, Inc.Represented Temasek in its investment of up to $150 million in biosimilar therapeutics company Coherus, Inc. (NASDAQ: CHRS), in a private placement transition.
Catalyst Biosciences, Inc. IPO/Reverse Merger and Public OfferingsRepresented Catalyst Biosciences, Inc. (NASDAQ: CBIO) in its IPO/reverse merger with Targacept and a $20.7 million underwritten public offering.
Restoration Hardware's Public OfferingsRepresented Restoration Hardware Holdings, Inc. (NYSE: RH), a luxury home furnishings retailer, as issuer's counsel on its initial public offering, two secondary offerings of common stock, and an offering of convertible notes for a combined $1.7 billion.
InvenSense's Public OfferingsRepresented InvenSense, Inc. (NYSE: INVN), a leading provider of motion processing solutions for consumer electronics, as issuer's counsel on its initial public offering, a follow-on offering of common stock and an offering of convertible senior notes for a combined $372 million.
Marrone Bio Innovations' Public OfferingsRepresented Marrone Bio Innovations, Inc. (NASDAQ: MBII), a leading provider of bio-based pest-management and plant health products, as issuer's counsel in an initial public offering, follow on common stock offerings and a private placement for a combined $168 million.
WaferGen's Registered Direct and Private Placement FinancingsRepresented WaferGen Bio-systems, Inc., a small-cap public company that develops genomic analysis systems, in its registered and private placement offerings completed in 2008 through 2011.
DURECT Corporation’s At-the-Market ProgramRepresented DURECT Corporation (Nasdaq: DRRX) in its adoption of a $25 million at-the-market offering program.
MERGERS & ACQUISITIONS
SoftBank's Acquisition of SprintRepresented SoftBank Corp. in its acquisition of a 70% stake in wireless operator Sprint Nextel Corporation for an enterprise value of $44.8 billion in the largest Asian acquisition or investment in the U.S.
Novellus' Merger with Lam ResearchRepresented Novellus Systems, Inc. in its stock-for-stock merger with Lam Research, Inc., estimated to be the fourth biggest semiconductor merger in 2011 at approximately $3.3 billion.
Shutterfly's Acquisition of Tiny PrintsRepresented Shutterfly, Inc. in its stock and cash acquisition of Tiny Prints, Inc., valued at approximately $460 million.
©1996-2019 Morrison & Foerster LLP. All rights reserved.